| abstract |
Peptides that specifically bind to erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind to erythrocytes, or as antibodies or fragments thereof that specifically bind to erythrocytes. The peptide may be prepared as a molecular fusion with a therapeutic agent, a tolerizing antigen or a targeting peptide. Tolerance can be caused by the use of fusions and the selection of antigens on the substance for which tolerance is desired. A fusion comprising a peptide directs the fusion to a target, eg, a tumor, where the red blood cell binding ligand recruits the red blood cells to the target to reduce or completely block blood flow to the tumor. |